These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 26352872)
21. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Ferraldeschi R; Minchell LJ; Roberts SA; Tobi S; Hadfield KD; Blackhall FH; Mullamitha S; Wilson G; Valle J; Saunders M; Newman WG Pharmacogenomics; 2009 May; 10(5):733-9. PubMed ID: 19450125 [TBL] [Abstract][Full Text] [Related]
22. Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan. Salvador-Martín S; García-González X; García MI; Blanco C; García-Alfonso P; Robles L; Grávalos C; Pachón V; Longo F; Martínez V; Sanjurjo-Sáez M; López-Fernández LA Pharmacol Res; 2018 Oct; 136():133-139. PubMed ID: 30213564 [TBL] [Abstract][Full Text] [Related]
23. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945 [TBL] [Abstract][Full Text] [Related]
24. Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. Cha PC; Mushiroda T; Zembutsu H; Harada H; Shinoda N; Kawamoto S; Shimoyama R; Nishidate T; Furuhata T; Sasaki K; Hirata K; Nakamura Y J Hum Genet; 2009 Oct; 54(10):572-80. PubMed ID: 19696792 [TBL] [Abstract][Full Text] [Related]
25. Irinogenetics: how many stars are there in the sky? Mathijssen RH; Gurney H J Clin Oncol; 2009 Jun; 27(16):2578-9. PubMed ID: 19349537 [No Abstract] [Full Text] [Related]
26. Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients. Mbatchi LC; Robert J; Ychou M; Boyer JC; Del Rio M; Gassiot M; Thomas F; Tubiana N; Evrard A Clin Pharmacokinet; 2016 Sep; 55(9):1145-57. PubMed ID: 27116457 [TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Zhou Q; Sparreboom A; Tan EH; Cheung YB; Lee A; Poon D; Lee EJ; Chowbay B Br J Clin Pharmacol; 2005 Apr; 59(4):415-24. PubMed ID: 15801936 [TBL] [Abstract][Full Text] [Related]
29. Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer. Paulík A; Grim J; Filip S Acta Medica (Hradec Kralove); 2012; 55(4):153-9. PubMed ID: 23631285 [TBL] [Abstract][Full Text] [Related]
30. Association Between ABCG2, ABCB1, ABCC2 Efflux Transporter Single-Nucleotide Variants and Irinotecan Adverse Effects in Patients With Colorectal Cancer: A Real-Life Study. Barnett-Griness O; Rennert G; Lejbkowicz F; Pinchev M; Saliba W; Gronich N Clin Pharmacol Ther; 2023 Mar; 113(3):704-711. PubMed ID: 36537755 [TBL] [Abstract][Full Text] [Related]
31. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Li M; Seiser EL; Baldwin RM; Ramirez J; Ratain MJ; Innocenti F; Kroetz DL Pharmacogenomics J; 2018 Jan; 18(1):35-42. PubMed ID: 27845419 [TBL] [Abstract][Full Text] [Related]
32. Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. Akiyama Y; Fujita K; Ishida H; Sunakawa Y; Yamashita K; Kawara K; Miwa K; Saji S; Sasaki Y Drug Metab Pharmacokinet; 2012; 27(3):325-35. PubMed ID: 22201120 [TBL] [Abstract][Full Text] [Related]
33. SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer. Huang L; Zhang T; Xie C; Liao X; Yu Q; Feng J; Ma H; Dai J; Li M; Chen J; Zang A; Wang Q; Ge S; Qin K; Cai J; Yuan X PLoS One; 2013; 8(10):e77223. PubMed ID: 24143213 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Di Paolo A; Bocci G; Polillo M; Del Re M; Di Desidero T; Lastella M; Danesi R Curr Drug Metab; 2011 Dec; 12(10):932-43. PubMed ID: 21787264 [TBL] [Abstract][Full Text] [Related]
35. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Sai K; Saito Y; Maekawa K; Kim SR; Kaniwa N; Nishimaki-Mogami T; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Matsumura Y; Ohtsu A; Saijo N; Minami H Cancer Chemother Pharmacol; 2010 May; 66(1):95-105. PubMed ID: 19771428 [TBL] [Abstract][Full Text] [Related]
36. Effect of UGT, SLCO, ABCB and ABCC polymorphisms on irinotecan toxicity. García Gil S; Ramos Díaz R; Nazco Casariego GJ; Llanos Muñoz M; Viña Romero MM; Martín Calero B; Pérez Pérez JA; Gutiérrez Nicolás F Med Clin (Barc); 2018 Dec; 151(11):425-430. PubMed ID: 29499902 [TBL] [Abstract][Full Text] [Related]
37. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology. Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010 [TBL] [Abstract][Full Text] [Related]
38. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238 [TBL] [Abstract][Full Text] [Related]
39. Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy. Sharma P; Singh N; Sharma S J Biochem Mol Toxicol; 2023 Mar; 37(3):e23269. PubMed ID: 36507589 [TBL] [Abstract][Full Text] [Related]
40. A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients. Li J; Yu Q; Fu S; Xu M; Zhang T; Xie C; Feng J; Chen J; Zang A; Cai Y; Fu Q; Liu S; Zhang M; Hong Q; Huang L; Yuan X J Cancer Res Clin Oncol; 2016 Jul; 142(7):1621-8. PubMed ID: 27160286 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]